|
|
|
|
Nitazoxanide (NTZ) may Mitigate the Unfavorable Association between IL28B Genotype and Hepatitis C Virus (HCV) Treatment Response to Pegylated Interferon- based (PEG) therapy
|
|
|
Reported by Jules Levin
CROI 2012 March 5-8 Seattle WA
AF Luetkemeyer1,T Umbleja2, V Amorosa3,4, B Abu-Dayyeh5, RT Chung6, M Kang2, M Bardin7,VA Johnson8, DW Haas9, MG Peters1, P Tebas4, Adult AIDS Clinical Trials Group (ACTG)5269 1University of California, San Francisco, 2Harvard School of Public Health, 3Philadelphia VA Medical Center, 4University of Pennsylvania 5Mayo Clinic, 6Massachusetts General Hospital, 7Romark Laboratories, Tampa, FL, 8Birmingam VA Medical Center and University of Alabama at Birmingham School of Medicine, 9Vanderbilt University
|
|
|
|
|
|
|